Harrow, Inc. Operating Leases, Future Minimum Payments Receivable, Remainder of Fiscal Year
Harrow, Inc. (HROW) had Operating Leases, Future Minimum Payments Receivable, Remainder of Fiscal Year of $132.00 thousand as of 2018-03-31, per its 10-Q filed 2018-05-15.
Discontinued › Notes › Leases
us-gaap:OperatingLeasesFutureMinimumPaymentsReceivableRemainderOfFiscalYear · last filed 2018-05-15
- 2018-03-31: Operating Leases, Future Minimum Payments Receivable, Remainder of Fiscal Year $132.00K.
- 2017-09-30: Operating Leases, Future Minimum Payments Receivable, Remainder of Fiscal Year $24.00K.
| Period end | Operating Leases, Future Minimum Payments Receivable, Remainder of Fiscal Year |
|---|---|
| 2018-03-31 | $132.00K 10-Q · filed 2018-05-15 |
| 2017-09-30 | $24.00K 10-Q · filed 2017-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |